Tests EXS73565 taken by mouth in adults with returning or resistant B-cell cancers
Tests EXS73565 taken by mouth in adults whose B-cell cancers returned or resisted treatment.
Plain-language title generated from the registry record
Registry title: Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Key facts
- Where
- Athens, Patras, and Thessaloniki, GreeceSee the 3 sites
- Phase
- Phase 1
Where in Greece
- Laiko General Hospital of AthensAthens, GreeceNo longer taking part
- General University Hospital Of PatrasPatras, GreeceNo longer taking part
- Geniko Nosokomeio Thessalonikis George PapanikolaouThessaloniki, GreeceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- Trial code
- NCT06980116EU 2024-516869-36-00
- Record updated
- 13 August 2026
- Original description
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.Read full original descriptionShow less
A Phase 1 Open-label, Multicenter, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of EXS73565 in Participants With Relapsed or Refractory B-cell Malignancies
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.
Inclusion: Age ≥18 years at the time of signing the informed consent; Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; Histologically confirmed diagnosis of one of the following B-cell malignancies: chronic lymphocytic leukemia (CLL), including Richter's transformation from CLL, mantle-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, or waldenström macroglobulinaemia; Participants that have relapsed after standard of care or have progressed during standard of care or are not suitable for standard of care therapy.
Exclusion: Received anticancer therapy, including chemotherapy, immunotherapy, radiation therapy (with the exception of palliative radiotherapy), biologic therapy, cancer-related hormonal therapy, or any investigational therapy within 14 days or 5 half-lives (whichever is shorter) before the first dose of the study treatment; Any medical or psychiatric condition that, in the view of the Principal Investigator, could jeopardize or would compromise the participant's safety or ability to participate in the study; Known central nervous system (CNS) malignancy or primary CNS lymphoma; Concurrent active or previous malignancy (other than the primary lymphoma/CLL for which the participant will be treated on this protocol within 5 years prior to randomization; participants with prior cancers may be enrolled with documented Sponsor approval.